GlassScriptPhysician profile
Tabatha Dominguez
NPI 1407325731
$3,055.05
in general payments reported to CMS, 2019-2025
21 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.74 · 2022: $312 · 2023: $629 · 2024: $833 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,545.36 |
| Education | $134.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $931.69 | 2022-2025 | |
| Novo Nordisk INC | $500.94 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $309.81 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $224.75 | 2023-2025 | Veozah |
| Lilly USA, LLC | $200.14 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $130.17 | 2024-2025 | Repatha, Prolia, Evenity |
| Merck Sharp & Dohme LLC | $119.16 | 2021-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $107.83 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $95.67 | 2024-2025 | |
| Exact Sciences Corporation | $89.71 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $89.43 | 2022-2025 | |
| Organon LLC | $37.25 | 2023-2025 | Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.52 | 2024-2025 | Jardiance |
| Smith+Nephew, INC. | $35.26 | 2024 | Collagenase Santyl |
| Currax Pharmaceuticals LLC | $31.66 | 2022-2025 | Contrave |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.73 | 2023-2024 | Entresto |
| Dexcom, INC. | $21.96 | 2025 | Dexcom G6 Transmitter |
| Ucb, INC. | $17.79 | 2024 | Nayzilam |
| Corium, LLC | $17.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.39 | 2024 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $13.62 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabatha Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.